Article

Novartis to market antibody fragment

Basel, Switzerland-Novartis Ophthalmics will have exclusive license to develop and market ranibizumab (Lucentis, formerly known as rhuFab V2), an anti-VEGF antibody fragment, outside North America under a new agreement with Genentech Inc.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
Related Content
Harrow launches partnership with mail-order pharmacy, PhilRx to expand access to VEVYE
March 17th 2025

Harrow launches partnership with mail-order pharmacy, PhilRx to expand access to VEVYE

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Stealth BioTherapeutics reaches 50 percent enrollment target in phase 3 ReNEW study
March 17th 2025

Stealth BioTherapeutics reaches 50 percent enrollment target in phase 3 ReNEW study

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Case report: Bilateral retinal detachments in a 19-year-old
March 17th 2025

Case report: Bilateral retinal detachments in a 19-year-old

ARVO announces recipients of the 2025 ARVO Foundation Early Career Clinician-Scientist Awards
March 16th 2025

ARVO announces recipients of the 2025 ARVO Foundation Early Career Clinician-Scientist Awards

© 2025 MJH Life Sciences

All rights reserved.